Table 2 Baseline demographic and clinical characteristics of CD patients

Gender, female, n (%)

27 (54.0)

Age, mean ± SD, years

34 ± 12

Montreal classification [26], n (%)

 A1, < 16 years

2 (4.0)

 A2, 17–40 years

40 (80.0)

 A3, > 40 years

8 (16.0)

 L1, ileal

30 (60.0)

 L2, colonic

0

 L3, ileocolonic

20 (40.0)

 L4, upper gastrointestinal disease

0

 B1, nonstricturing, nonpenetrating

22 (44.0)

 B2, stricturing

17 (34.0)

 B3, penetrating

11 (22.0)

HBI, mean ± SD

5 ± 4

 Clinical remission (HBI < 5), n (%)

26 (52.0)

 Clinically active disease (HBI ≥ 5), n (%)

24 (48.0)

SES-CD, mean ± SD

7 ± 4

 Active disease (SES-CD ≥ 7), n (%)

30 (60.0)

 Inactive disease (SES-CD < 7), n (%)

20 (40.0)

CRP, mean ± SD (mg/L)

21.2 ± 32.7

 CRP > 3.0 mg/L, n (%)

42 (84.0)

Fecal calprotectin, mean ± SD (μg/g)

857 ± 610

 Fecal calprotectin ≥ 150 μg/g, n (%)

38 (76.0)